NeOnc Technologies Holdings, Inc. (NTHI)
NASDAQ: NTHI · Real-Time Price · USD
3.300
+0.140 (4.43%)
At close: Sep 29, 2026, 4:00 PM EDT
3.250
-0.050 (-1.52%)
After-hours: Sep 29, 2026, 7:48 PM EDT
NTHI Revenue
NeOnc Technologies Holdings had revenue of $39.99K in the twelve months ending June 30, 2026, up 99.95% year-over-year. In the year 2025, NeOnc Technologies Holdings had annual revenue of $39.99K, down -51.82%.
Revenue (ttm)
$39.99K
Revenue Growth
+99.95%
P/S Ratio
2,051.20
Revenue / Employee
$7,998
Employees
5
Market Cap
82.03M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 39.99K | -43.01K | -51.82% |
| Dec 31, 2024 | 83.00K | 12.54K | 17.79% |
| Dec 31, 2023 | 70.46K | 50.46K | 252.31% |
| Dec 31, 2022 | 20.00K | - | - |
| Dec 31, 2021 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Fortress Biotech | 68.47M |
| Pelthos Therapeutics | 43.30M |
| Atara Biotherapeutics | 6.19M |
| Rallybio | 646.00K |
| iBio, Inc. | 100.00K |
| Fractyl Health | 3.00K |
NTHI News
- 18 hours ago - NeOnc Technologies announces brain cancer pipeline advances - TheFly
- 19 hours ago - NeOnc's Powerful Brain Cancer Pipeline Advances - GlobeNewsWire
- 1 day ago - Powerful NeOnc Brain Cancer Pipeline Advances - GlobeNewsWire
- 1 day ago - NeOnc Technologies Announces FDA End of Phase 1 Meeting for NEO212 - GlobeNewsWire
- 5 days ago - NeOnc Lands New Coverage and Roth Sees Potential 2026 Trial Catalyst - GlobeNewsWire
- 5 days ago - NeOnc Technologies initiated with a Buy at Roth Capital - TheFly
- 7 days ago - NeOnc's Delivery may Finally Change the Equation for Brain Cancer's Next Frontier - GlobeNewsWire
- 8 days ago - NeOnc Charting New Nasal Route to Treating Brain Cancer - GlobeNewsWire